GLMDHealthcare · Biotechnology

GLMD Stock Forecast: Galmed Pharmaceuticals Ltd. Price Predictions for 2026-2027

Last close, 21 Aug 2026

$4.31

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 19 of 100 as at 22 Aug 2026 — in the weakest quartile.

Market cap

$4.5M

Ticker Nerd rank

19 / 100

Median analyst target

—

Analysts covering

Ticker Nerd rank

GLMD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Galmed Pharmaceuticals Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

19 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Quality

Growth

Momentum

Revisions

Issuance

Volatility

Value

Size (97): Smaller than most of the companies we track.

Value (5): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

GLMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GLMD, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says1 analysts

0 Buy1 Hold0 Sell

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
4 Apr 2025	Maxim Group	Downgrade	Hold	—
24 July 2023	Maxim Group	Upgrade	Buy	—
8 Aug 2022	Canaccord Genuity	Downgrade	Hold	—
8 Aug 2022	Maxim Group	Downgrade	Hold	—
18 May 2022	Raymond James	Downgrade	Market Perform	—
3 May 2022	HC Wainwright & Co.	Downgrade	Neutral	—
3 May 2022	Raymond James	Maintains	Outperform	—
17 May 2021	Canaccord Genuity	Maintains	Buy	—
19 Mar 2021	HC Wainwright & Co.	Maintains	Buy	—
8 Jan 2021	Raymond James	Maintains	Outperform	—
25 Nov 2020	Canaccord Genuity	Maintains	Buy	—
22 May 2020	B. Riley FBR	Downgrade	Neutral	—
22 May 2020	B. Riley Securities	Downgrade	Neutral	—
15 May 2020	Raymond James	Maintains	Outperform	—
13 Mar 2020	B. Riley FBR	Maintains	Buy	—
13 Mar 2020	B. Riley Securities	Maintains	Buy	—
13 Mar 2020	Stifel	Maintains	Buy	—
4 Feb 2020	Craig-Hallum	Initiates	Buy	—
30 Jan 2020	Cantor Fitzgerald	Assumes	Overweight	$59 → $14
22 July 2019	Laidlaw & Co.	Initiates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GLMD appears on the weeks it earns a place.

Estimates

GLMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Galmed Pharmaceuticals Ltd. (GLMD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 0.0×
Price / sales: —
Price / book: 2.0×
EV / EBITDA: 2.0×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −72.1%
Return on assets: −33.5%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

GLMD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
GLMDGalmed Pharmaceuticals Ltd.	$4.5M	19
JAGXJaguar Health, Inc.	$4.5M	57
MBIOMustang Bio, Inc.	$4.4M	13
TCRTAlaunos Therapeutics, Inc.	$4.3M	31
REVBRevelation Biosciences, Inc.	$4.3M	8
VIVSVivoSim Labs, Inc.	$4.7M	30
GOVXGeoVax Labs, Inc.	$4.8M	29

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Galmed Pharmaceuticals Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GLMD news & analysis

Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology

PRNewsWire · 19 Aug 2026positive

Galmed announced successful first-in-human proof-of-concept clinical study results for Colospan's novel intraoperative tissue assessment technology. The prospective, single-arm study enrolled 32 colorectal cancer patients at three clinical centers in Israel and demonstrated feasibility of intraoperative quantitative measurement of colon tissue quality.

Why it matters — Galmed watchers would care because these positive early clinical results for Colospan's technology represent a key development milestone in Galmed's portfolio.

Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models

PRNewsWire · 17 Aug 2026positive

Galmed Pharmaceuticals announced first-time results from prostate oncology studies, reporting that Aramchol demonstrated a 3-4 fold increase in cell death compared to enzalutamide (Xtandi) alone in prostate cancer models. The release also noted Xtandi's global sales figures of approximately $8 billion in 2024 and $6 billion in 2025.

Why it matters — A GLMD watcher would care because these early preclinical results suggest Aramchol could have potential beyond its existing indications, positioning the company in a large oncology market.

Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market

PRNewsWire · 28 July 2026positive

Galmed Pharmaceuticals announced the development of an orally dispersible film (ODF) formulation of its SCD1 inhibitor Aramchol for Parkinson's disease, which showed higher systemic bioavailability and increased central nervous system exposure compared to conventional oral administration in testing.

Why it matters — This development expands Galmed's pipeline beyond liver indications into neurodegenerative disease, potentially opening a new and large addressable market for the company's lead compound.

FAQ

Frequently asked questions about GLMD stock

Is GLMD stock a buy right now?

Of the 1 analysts covering Galmed Pharmaceuticals Ltd., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Galmed Pharmaceuticals Ltd. 19 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GLMD?

As at 22 Aug 2026, Galmed Pharmaceuticals Ltd. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).

What is the GLMD stock forecast for 2030?

No analyst covering Galmed Pharmaceuticals Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GLMD are extrapolating price history, which says nothing about the business.

What does Galmed Pharmaceuticals Ltd. do?

What is the latest news on GLMD?

The most recent item we track (PRNewsWire, 19 Aug 2026): "Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology". Galmed announced successful first-in-human proof-of-concept clinical study results for Colospan's novel intraoperative tissue assessment technology. The prospective, single-arm study enrolled 32 colorectal cancer patients at three clinical centers in Israel and demonstrated feasibility of intraoperative quantitative measurement of colon tissue quality.

Company

About Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutic solutions in the healthcare industry, particularly focusing on liver diseases. Its primary aim is to address the unmet medical needs in the field of liver and metabolic diseases through innovative therapies. Galmed is notably recognized for its pioneering work on Aramchol, an investigational orally available drug, targeting Nonalcoholic Steatohepatitis (NASH) and other liver disorders. This therapeutic candidate plays a vital role in modulating lipid metabolism in the liver, which is a critical factor in the progression of NASH. Headquartered in Israel, Galmed Pharmaceuticals is at the forefront of research and development within its specialized niche, contributing significantly to the global biopharmaceutical landscape. The company's focus on niche markets like NASH underscores its strategic importance in potentially driving advancements in therapeutic options where current treatment paths are limited or non-existent, thus underscoring its potential impact on healthcare outcomes.

CEO Mr. Allen Baharaff · 3 employees · Israel · https://galmedpharma.com